Interactions between synthetic vanilloids and the endogenous cannabinoid system

V Di Marzo, T Bisogno, D Melck, Ruth Alexandra Ross, H Brockie, Lesley Ann Stevenson, Roger Guy Pertwee, L De Petrocellis

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

The chemical similarity between some synthetic agonists of vanilloid receptors, such as olvanil (N-vanillyl-cis-9-octadecenoamide), and the 'endocannabinoid' anandamide (arachidonoyl-ethanolamide, AEA), suggests possible interactions between the cannabinoid and vanilloid signalling systems. Here we report that olvanil is a stable and potent inhibitor of AEA facilitated transport into rat basophilic leukemia (RBL-2H3) cells, Olvanil blocked both the uptake and the hydrolysis of [C-14]AEA by intact RBL-2H3 cells (IC50=9 mu M), while capsaicin and pseudocapsaicin (N-vanillyl-nonanamide) were much less active. Olvanil was more potent than previously reported inhibitors of AEA facilitated transport, i,e; phloretin (IC50=80 mu M), AM404 (12.9% inhibition at 10 mu M) or oleoylethamolamide (27.5% inhibition at 10 mu M) Olvanil was a poor inhibitor of [C-14]AEA hydrolysis by RBL-2H3 and N18TG2 cell membranes, suggesting that the inhibitory effect on [C-14]AEA breakdown observed in intact cells vr,as due to inhibition of [C-14]AEA uptake. Olvanil was stable to enzymatic hydrolysis, and (i) displaced the binding of high affinity cannabinoid receptor ligands to membrane preparations from N18TG2 cells and guinea pig forebrain (K-i = 1.64-7.08 mu M), but not from cells expressing the CB2 cannabinoid receptor subtype; (ii) inhibited forskolin-induced cAMP formation in intact N18TG2 cells (IC50 = 1.60 mu M), this effect being reversed by the selective CB1 antagonist SR141716A. Pseudocapsaicin, but not capsaicin, also selectively bound to CB1 receptor-containing membranes. These data suggest that some of the analgesic actions of olvanil may be due to its interactions with the endogenous cannabinoid system, and may lead to the design of a novel class of cannabimimetics with potential therapeutic applications as analgesics. (C) 1998 Federation of European Biochemical Societies.

Original languageEnglish
Pages (from-to)449-454
Number of pages6
JournalFEBS Letters
Volume436
Issue number3
DOIs
Publication statusPublished - 9 Oct 1998

Keywords

  • vanilloid receptor
  • cannabinoid receptor
  • endocannabinoid
  • anandamide
  • capsaicin
  • inflammation
  • antinociception
  • mast cell
  • MOLECULAR CHARACTERIZATION
  • CB1 RECEPTORS
  • ANANDAMIDE
  • CAPSAICIN
  • OLVANIL
  • MOUSE
  • BRAIN
  • PALMITOYLETHANOLAMIDE
  • INHIBITION
  • NE-19550
  • vanilloid receptor
  • cannabinoid receptor;
  • inflammation

Cite this

Di Marzo, V., Bisogno, T., Melck, D., Ross, R. A., Brockie, H., Stevenson, L. A., ... De Petrocellis, L. (1998). Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Letters, 436(3), 449-454. https://doi.org/10.1016/S0014-5793(98)01175-2

Interactions between synthetic vanilloids and the endogenous cannabinoid system. / Di Marzo, V ; Bisogno, T ; Melck, D ; Ross, Ruth Alexandra; Brockie, H ; Stevenson, Lesley Ann; Pertwee, Roger Guy; De Petrocellis, L .

In: FEBS Letters, Vol. 436, No. 3, 09.10.1998, p. 449-454.

Research output: Contribution to journalArticle

Di Marzo, V, Bisogno, T, Melck, D, Ross, RA, Brockie, H, Stevenson, LA, Pertwee, RG & De Petrocellis, L 1998, 'Interactions between synthetic vanilloids and the endogenous cannabinoid system', FEBS Letters, vol. 436, no. 3, pp. 449-454. https://doi.org/10.1016/S0014-5793(98)01175-2
Di Marzo V, Bisogno T, Melck D, Ross RA, Brockie H, Stevenson LA et al. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Letters. 1998 Oct 9;436(3):449-454. https://doi.org/10.1016/S0014-5793(98)01175-2
Di Marzo, V ; Bisogno, T ; Melck, D ; Ross, Ruth Alexandra ; Brockie, H ; Stevenson, Lesley Ann ; Pertwee, Roger Guy ; De Petrocellis, L . / Interactions between synthetic vanilloids and the endogenous cannabinoid system. In: FEBS Letters. 1998 ; Vol. 436, No. 3. pp. 449-454.
@article{d290b51b69f24888a23c3377fc14e5c5,
title = "Interactions between synthetic vanilloids and the endogenous cannabinoid system",
abstract = "The chemical similarity between some synthetic agonists of vanilloid receptors, such as olvanil (N-vanillyl-cis-9-octadecenoamide), and the 'endocannabinoid' anandamide (arachidonoyl-ethanolamide, AEA), suggests possible interactions between the cannabinoid and vanilloid signalling systems. Here we report that olvanil is a stable and potent inhibitor of AEA facilitated transport into rat basophilic leukemia (RBL-2H3) cells, Olvanil blocked both the uptake and the hydrolysis of [C-14]AEA by intact RBL-2H3 cells (IC50=9 mu M), while capsaicin and pseudocapsaicin (N-vanillyl-nonanamide) were much less active. Olvanil was more potent than previously reported inhibitors of AEA facilitated transport, i,e; phloretin (IC50=80 mu M), AM404 (12.9{\%} inhibition at 10 mu M) or oleoylethamolamide (27.5{\%} inhibition at 10 mu M) Olvanil was a poor inhibitor of [C-14]AEA hydrolysis by RBL-2H3 and N18TG2 cell membranes, suggesting that the inhibitory effect on [C-14]AEA breakdown observed in intact cells vr,as due to inhibition of [C-14]AEA uptake. Olvanil was stable to enzymatic hydrolysis, and (i) displaced the binding of high affinity cannabinoid receptor ligands to membrane preparations from N18TG2 cells and guinea pig forebrain (K-i = 1.64-7.08 mu M), but not from cells expressing the CB2 cannabinoid receptor subtype; (ii) inhibited forskolin-induced cAMP formation in intact N18TG2 cells (IC50 = 1.60 mu M), this effect being reversed by the selective CB1 antagonist SR141716A. Pseudocapsaicin, but not capsaicin, also selectively bound to CB1 receptor-containing membranes. These data suggest that some of the analgesic actions of olvanil may be due to its interactions with the endogenous cannabinoid system, and may lead to the design of a novel class of cannabimimetics with potential therapeutic applications as analgesics. (C) 1998 Federation of European Biochemical Societies.",
keywords = "vanilloid receptor, cannabinoid receptor, endocannabinoid, anandamide, capsaicin, inflammation, antinociception, mast cell, MOLECULAR CHARACTERIZATION, CB1 RECEPTORS, ANANDAMIDE, CAPSAICIN, OLVANIL, MOUSE, BRAIN, PALMITOYLETHANOLAMIDE, INHIBITION, NE-19550, vanilloid receptor, cannabinoid receptor;, inflammation",
author = "{Di Marzo}, V and T Bisogno and D Melck and Ross, {Ruth Alexandra} and H Brockie and Stevenson, {Lesley Ann} and Pertwee, {Roger Guy} and {De Petrocellis}, L",
year = "1998",
month = "10",
day = "9",
doi = "10.1016/S0014-5793(98)01175-2",
language = "English",
volume = "436",
pages = "449--454",
journal = "FEBS Letters",
issn = "0014-5793",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Interactions between synthetic vanilloids and the endogenous cannabinoid system

AU - Di Marzo, V

AU - Bisogno, T

AU - Melck, D

AU - Ross, Ruth Alexandra

AU - Brockie, H

AU - Stevenson, Lesley Ann

AU - Pertwee, Roger Guy

AU - De Petrocellis, L

PY - 1998/10/9

Y1 - 1998/10/9

N2 - The chemical similarity between some synthetic agonists of vanilloid receptors, such as olvanil (N-vanillyl-cis-9-octadecenoamide), and the 'endocannabinoid' anandamide (arachidonoyl-ethanolamide, AEA), suggests possible interactions between the cannabinoid and vanilloid signalling systems. Here we report that olvanil is a stable and potent inhibitor of AEA facilitated transport into rat basophilic leukemia (RBL-2H3) cells, Olvanil blocked both the uptake and the hydrolysis of [C-14]AEA by intact RBL-2H3 cells (IC50=9 mu M), while capsaicin and pseudocapsaicin (N-vanillyl-nonanamide) were much less active. Olvanil was more potent than previously reported inhibitors of AEA facilitated transport, i,e; phloretin (IC50=80 mu M), AM404 (12.9% inhibition at 10 mu M) or oleoylethamolamide (27.5% inhibition at 10 mu M) Olvanil was a poor inhibitor of [C-14]AEA hydrolysis by RBL-2H3 and N18TG2 cell membranes, suggesting that the inhibitory effect on [C-14]AEA breakdown observed in intact cells vr,as due to inhibition of [C-14]AEA uptake. Olvanil was stable to enzymatic hydrolysis, and (i) displaced the binding of high affinity cannabinoid receptor ligands to membrane preparations from N18TG2 cells and guinea pig forebrain (K-i = 1.64-7.08 mu M), but not from cells expressing the CB2 cannabinoid receptor subtype; (ii) inhibited forskolin-induced cAMP formation in intact N18TG2 cells (IC50 = 1.60 mu M), this effect being reversed by the selective CB1 antagonist SR141716A. Pseudocapsaicin, but not capsaicin, also selectively bound to CB1 receptor-containing membranes. These data suggest that some of the analgesic actions of olvanil may be due to its interactions with the endogenous cannabinoid system, and may lead to the design of a novel class of cannabimimetics with potential therapeutic applications as analgesics. (C) 1998 Federation of European Biochemical Societies.

AB - The chemical similarity between some synthetic agonists of vanilloid receptors, such as olvanil (N-vanillyl-cis-9-octadecenoamide), and the 'endocannabinoid' anandamide (arachidonoyl-ethanolamide, AEA), suggests possible interactions between the cannabinoid and vanilloid signalling systems. Here we report that olvanil is a stable and potent inhibitor of AEA facilitated transport into rat basophilic leukemia (RBL-2H3) cells, Olvanil blocked both the uptake and the hydrolysis of [C-14]AEA by intact RBL-2H3 cells (IC50=9 mu M), while capsaicin and pseudocapsaicin (N-vanillyl-nonanamide) were much less active. Olvanil was more potent than previously reported inhibitors of AEA facilitated transport, i,e; phloretin (IC50=80 mu M), AM404 (12.9% inhibition at 10 mu M) or oleoylethamolamide (27.5% inhibition at 10 mu M) Olvanil was a poor inhibitor of [C-14]AEA hydrolysis by RBL-2H3 and N18TG2 cell membranes, suggesting that the inhibitory effect on [C-14]AEA breakdown observed in intact cells vr,as due to inhibition of [C-14]AEA uptake. Olvanil was stable to enzymatic hydrolysis, and (i) displaced the binding of high affinity cannabinoid receptor ligands to membrane preparations from N18TG2 cells and guinea pig forebrain (K-i = 1.64-7.08 mu M), but not from cells expressing the CB2 cannabinoid receptor subtype; (ii) inhibited forskolin-induced cAMP formation in intact N18TG2 cells (IC50 = 1.60 mu M), this effect being reversed by the selective CB1 antagonist SR141716A. Pseudocapsaicin, but not capsaicin, also selectively bound to CB1 receptor-containing membranes. These data suggest that some of the analgesic actions of olvanil may be due to its interactions with the endogenous cannabinoid system, and may lead to the design of a novel class of cannabimimetics with potential therapeutic applications as analgesics. (C) 1998 Federation of European Biochemical Societies.

KW - vanilloid receptor

KW - cannabinoid receptor

KW - endocannabinoid

KW - anandamide

KW - capsaicin

KW - inflammation

KW - antinociception

KW - mast cell

KW - MOLECULAR CHARACTERIZATION

KW - CB1 RECEPTORS

KW - ANANDAMIDE

KW - CAPSAICIN

KW - OLVANIL

KW - MOUSE

KW - BRAIN

KW - PALMITOYLETHANOLAMIDE

KW - INHIBITION

KW - NE-19550

KW - vanilloid receptor

KW - cannabinoid receptor;

KW - inflammation

U2 - 10.1016/S0014-5793(98)01175-2

DO - 10.1016/S0014-5793(98)01175-2

M3 - Article

VL - 436

SP - 449

EP - 454

JO - FEBS Letters

JF - FEBS Letters

SN - 0014-5793

IS - 3

ER -